Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple Dose Safety and PK of WCK 4282 (FEP-TAZ) in Healthy Volunteers
NCT03622008Phase 1Completed
- Sponsor
- Wockhardt
- Start
- Mar 2018
- Primary completion
- May 2018
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in complicated urinary tract infection (cUTI) and Gram-negative bacterial infection comparing FEP-TAZ 4 g with Placebo (2 arms). Primary endpoints: Number of abnormal clinical laboratory test results, Maximum Concentration and 4 more. Started Mar 2018; status: completed.
02
Drugs
cefepime + tazobactam
03
Conditions
complicated urinary tract infection (cUTI)Gram-negative bacterial infection
Beyond the preview
Go deeper on NCT03622008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03622008.